Form Type:  SC 13G/A
Filing Date:  7/11/2022 
CIK:  0001654151 
Address:  200 SMITH STREET 
City, State, Zip:  WALTHAM, Massachusetts 02451 
Telephone:  781-209-6400 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.52 (3.37%)  
Trade Time: 
Nov 25  
Market Cap: 
Trade DCPH now with 

© 2022  
Description of Business
We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology, we design kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines. Through our patient-inspired approach, we seek to develop a broad portfolio of innovative medicines to improve treatment outcomes. QINLOCK, our switch-control kinase inhibitor, was engineered using our proprietary drug discovery platform and developed for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union (EU), Hong Kong, Switzerland, Taiwan, the United States (U.S.), and the United Kingdom (U.K.) for the treatment of fourth-line GIST.
Register and access this filing in: